RU2017121191A - Методика размножения гамма-дельта Т-клеток - Google Patents
Методика размножения гамма-дельта Т-клеток Download PDFInfo
- Publication number
- RU2017121191A RU2017121191A RU2017121191A RU2017121191A RU2017121191A RU 2017121191 A RU2017121191 A RU 2017121191A RU 2017121191 A RU2017121191 A RU 2017121191A RU 2017121191 A RU2017121191 A RU 2017121191A RU 2017121191 A RU2017121191 A RU 2017121191A
- Authority
- RU
- Russia
- Prior art keywords
- cells
- medium
- activator
- preceding paragraphs
- serum
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 23
- 210000004475 gamma-delta t lymphocyte Anatomy 0.000 title 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 239000002609 medium Substances 0.000 claims 5
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 4
- 239000012190 activator Substances 0.000 claims 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims 4
- 230000000644 propagated effect Effects 0.000 claims 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000000259 anti-tumor effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 1
- 229940122361 Bisphosphonate Drugs 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 150000004663 bisphosphonates Chemical group 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000003162 effector t lymphocyte Anatomy 0.000 claims 1
- 230000002349 favourable effect Effects 0.000 claims 1
- 239000012091 fetal bovine serum Substances 0.000 claims 1
- 239000012894 fetal calf serum Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000012679 serum free medium Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims 1
- 229960004276 zoledronic acid Drugs 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/49—Breast
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/42—Organic phosphate, e.g. beta glycerophosphate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1421716.0A GB201421716D0 (en) | 2014-12-05 | 2014-12-05 | Cell expansion procedure |
| GB1421716.0 | 2014-12-05 | ||
| PCT/GB2015/053713 WO2016087871A1 (en) | 2014-12-05 | 2015-12-04 | Gammadelta t cell expansion procedure |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017121191A true RU2017121191A (ru) | 2019-01-10 |
| RU2017121191A3 RU2017121191A3 (https=) | 2019-07-29 |
Family
ID=52425560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017121191A RU2017121191A (ru) | 2014-12-05 | 2015-12-04 | Методика размножения гамма-дельта Т-клеток |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US10557117B2 (https=) |
| EP (2) | EP3696263A1 (https=) |
| JP (1) | JP6802159B2 (https=) |
| KR (1) | KR102686005B1 (https=) |
| CN (1) | CN107208061B (https=) |
| AU (1) | AU2015356788B2 (https=) |
| CA (1) | CA2969783C (https=) |
| DK (1) | DK3227435T3 (https=) |
| GB (1) | GB201421716D0 (https=) |
| MX (1) | MX392057B (https=) |
| RU (1) | RU2017121191A (https=) |
| WO (1) | WO2016087871A1 (https=) |
| ZA (1) | ZA201704499B (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201421716D0 (en) | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
| KR102032354B1 (ko) * | 2016-11-11 | 2019-10-16 | 가톨릭대학교 산학협력단 | 신규한 배양보조세포 및 이를 이용한 감마 델타 ｔ 세포의 증식 방법 |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| CN108588023B (zh) | 2018-05-09 | 2020-02-14 | 河北森朗生物科技有限公司 | 一种生产嵌合抗原受体修饰的γδT细胞的方法 |
| TW202020145A (zh) | 2018-07-13 | 2020-06-01 | 國立大學法人京都大學 | γδＴ細胞的製造方法 |
| CA3114292A1 (en) * | 2018-09-27 | 2020-04-02 | Phosphogam, Inc. | Methods and compositions for the expansion and use of allogeneic gamma/delta-t cells |
| CN109234236A (zh) * | 2018-09-29 | 2019-01-18 | 吉林大学第医院 | 一种嵌合抗原受体γδT细胞的制备方法 |
| SG11202104692VA (en) * | 2018-11-08 | 2021-06-29 | In8Bio Inc | Compositions and methods for treating cancer |
| CN110184240B (zh) * | 2019-06-13 | 2020-11-20 | 上海市肺科医院 | 一种高效扩增活化Vγ2Vδ2 T细胞增强其抗结核活性的方法 |
| CA3162755A1 (en) | 2019-11-25 | 2021-06-03 | Kyoto University | T-cell master cell bank |
| US11999968B2 (en) | 2021-10-22 | 2024-06-04 | Fullhope Biomedical Co., Ltd | Modified T cells, pharmaceutical composition, manufacturing method thereof, and method of using the same |
| KR20230105166A (ko) * | 2022-01-03 | 2023-07-11 | 주식회사 이뮤노맥스 | 감마-델타 t 세포의 증식 배양 방법 |
| CN114645022B (zh) * | 2022-05-13 | 2022-09-02 | 首都医科大学宣武医院 | 靶向CD5的CAR-γ δ T细胞及其制备方法与应用 |
| JP2025064863A (ja) * | 2023-10-06 | 2025-04-17 | 株式会社マイオリッジ | Ｔ細胞の培養方法 |
| JP7725011B1 (ja) * | 2024-02-01 | 2025-08-19 | ミヤリサン製薬株式会社 | Ｃｄ４－ｃｄ８－ｔ細胞を増殖および／または活性化させるための組成物 |
| CN120924492B (zh) * | 2025-10-15 | 2026-03-03 | 瑞因细胞工程科技(广州)有限公司 | 一种脐血来源γδT细胞的体外诱导组合物及培养方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7256498A (en) | 1997-04-25 | 1998-11-24 | Wistar Institute Of Anatomy And Biology, The | Cytolytic t-cell clones against colorectal carcinoma and methods of use thereof |
| AU747767B2 (en) * | 1997-11-05 | 2002-05-23 | University Of Southern California | Use of cytokines and mitogens to inhibit pathological immune responses |
| ATE421573T1 (de) * | 1998-11-04 | 2009-02-15 | Therapure Biopharma Inc | Verfahren zur herstellung von gamma delta t zellen |
| US20030157060A1 (en) * | 2000-04-03 | 2003-08-21 | Bell David N | Production of tcr gamma delta t cells |
| FR2836483B1 (fr) | 2002-02-22 | 2006-09-15 | Innate Pharma | Procedes de production de lymphocytes gamma delta t |
| EP1426052B1 (en) | 2002-12-02 | 2009-09-02 | Innate Pharma | Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof |
| EP1720567A2 (en) | 2004-02-10 | 2006-11-15 | Innate Pharma | Composition and method for the treatment of carcinoma |
| WO2006006720A1 (ja) * | 2004-07-13 | 2006-01-19 | Medinet., Co.Ltd | γδＴ細胞の培養方法、γδＴ細胞及び治療・予防剤 |
| DE602005022728D1 (de) * | 2004-08-19 | 2010-09-16 | Univ Cardiff | Präparation antigenpräsentierender menschlicher gamma delta t-zellen und verwendung in der immuntherapie |
| AU2006272647A1 (en) | 2005-07-25 | 2007-02-01 | Therimunex Pharmaceuticals, Inc. | Peptidyl diacylglycerides |
| WO2008059052A1 (en) * | 2006-11-17 | 2008-05-22 | Innate Pharma | Improved methods of using phosphoantigen for the treatment of cancer |
| WO2008129874A1 (ja) * | 2007-04-13 | 2008-10-30 | Medinet Co., Ltd. | 腫瘍細胞の標的化方法、及びその用途 |
| ITRM20070437A1 (it) * | 2007-08-10 | 2009-02-11 | Istituto Naz Per Le Malattie I | Metodo per la generazione ed espansione di cellule t gamma/delta regolatorie cellule cosi' ottenute e loro impieghi |
| WO2009131730A2 (en) | 2008-01-31 | 2009-10-29 | University Of Iowa Research Foundation | IMMUNOGENIC COMPOSITIONS FOR ACTIVATING γδ T CELLS |
| US8962313B2 (en) * | 2008-07-01 | 2015-02-24 | Medinet Co., Ltd. | Method for the simultaneous induction of CTL and γδT cell |
| US8828944B2 (en) | 2010-04-22 | 2014-09-09 | Institut Gustave Roussy | Compounds and uses thereof to induce an immunogenic cancer cell death in a subject |
| WO2012131419A1 (en) * | 2011-03-25 | 2012-10-04 | Txcell | Method for using regulatory t cells in therapy |
| US10584158B2 (en) | 2013-04-17 | 2020-03-10 | Baylor College Of Medicine | Immunosuppressive TGF-β signal converter |
| CN103436492B (zh) * | 2013-08-02 | 2016-03-02 | 北京赛诺泰生物科技有限公司 | 通过无血清培养扩增活化淋巴细胞的方法 |
| CN103436493B (zh) * | 2013-08-29 | 2016-02-03 | 浙江大学 | 雷帕霉素诱导调节性γδT细胞的培养方法 |
| GB201421716D0 (en) | 2014-12-05 | 2015-01-21 | King S College London | Cell expansion procedure |
-
2014
- 2014-12-05 GB GBGB1421716.0A patent/GB201421716D0/en not_active Ceased
-
2015
- 2015-12-04 MX MX2017007214A patent/MX392057B/es unknown
- 2015-12-04 EP EP20152991.4A patent/EP3696263A1/en not_active Withdrawn
- 2015-12-04 CN CN201580072217.6A patent/CN107208061B/zh active Active
- 2015-12-04 WO PCT/GB2015/053713 patent/WO2016087871A1/en not_active Ceased
- 2015-12-04 EP EP15819849.9A patent/EP3227435B1/en active Active
- 2015-12-04 RU RU2017121191A patent/RU2017121191A/ru not_active Application Discontinuation
- 2015-12-04 CA CA2969783A patent/CA2969783C/en active Active
- 2015-12-04 DK DK15819849.9T patent/DK3227435T3/da active
- 2015-12-04 JP JP2017529381A patent/JP6802159B2/ja active Active
- 2015-12-04 AU AU2015356788A patent/AU2015356788B2/en active Active
- 2015-12-04 US US15/532,921 patent/US10557117B2/en active Active
- 2015-12-04 KR KR1020177018323A patent/KR102686005B1/ko active Active
-
2017
- 2017-07-03 ZA ZA2017/04499A patent/ZA201704499B/en unknown
-
2019
- 2019-12-18 US US16/719,625 patent/US20200140816A1/en not_active Abandoned
- 2019-12-18 US US16/719,650 patent/US11566222B2/en active Active
-
2023
- 2023-01-23 US US18/158,146 patent/US20230323298A1/en not_active Abandoned
-
2024
- 2024-11-29 US US18/964,041 patent/US20250092364A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3696263A1 (en) | 2020-08-19 |
| RU2017121191A3 (https=) | 2019-07-29 |
| AU2015356788A1 (en) | 2017-07-13 |
| GB201421716D0 (en) | 2015-01-21 |
| US11566222B2 (en) | 2023-01-31 |
| CA2969783C (en) | 2023-08-01 |
| CA2969783A1 (en) | 2016-06-09 |
| MX392057B (es) | 2025-03-21 |
| US20200123502A1 (en) | 2020-04-23 |
| US10557117B2 (en) | 2020-02-11 |
| ZA201704499B (en) | 2019-09-25 |
| US20170342381A1 (en) | 2017-11-30 |
| US20230323298A1 (en) | 2023-10-12 |
| CN107208061B (zh) | 2025-11-18 |
| AU2015356788B2 (en) | 2021-09-30 |
| KR20170084337A (ko) | 2017-07-19 |
| US20200140816A1 (en) | 2020-05-07 |
| US20250092364A1 (en) | 2025-03-20 |
| JP2017537625A (ja) | 2017-12-21 |
| CN107208061A (zh) | 2017-09-26 |
| WO2016087871A1 (en) | 2016-06-09 |
| MX2017007214A (es) | 2018-01-30 |
| EP3227435B1 (en) | 2020-01-29 |
| KR102686005B1 (ko) | 2024-07-17 |
| JP6802159B2 (ja) | 2020-12-16 |
| EP3227435A1 (en) | 2017-10-11 |
| DK3227435T3 (da) | 2020-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017121191A (ru) | Методика размножения гамма-дельта Т-клеток | |
| JP2017537625A5 (https=) | ||
| Mandal et al. | Natural killer cells: In health and disease | |
| AU2018240515A1 (en) | Nucleic acids encoding CRISPR-associated proteins and uses thereof | |
| HRP20230424T1 (hr) | Postupci i pripravci za prirodnoubilačke stanice | |
| TR201903587T4 (tr) | Telomeraz aktivitesinin artırılması için bileşimler. | |
| Ballesteros-Tato et al. | Mechanisms of action of low-dose IL-2 restoration therapies in SLE | |
| WO2015049688A3 (en) | Patient-specific immunotherapy for treating heterogeneous tumors | |
| CN105934155A (zh) | 在调节疼痛和/或纤维化中使用脂肪组织来源的细胞的方法 | |
| JP2010220479A (ja) | Ｎｋ細胞の培養方法及びｎｋ細胞の利用 | |
| AU2022228188A1 (en) | Modulating inflammasome activation of myeloid-derived suppressor cells for treating gvhd or tumor | |
| KR20170124467A (ko) | 저산소 조건을 이용한 면역세포의 증식 배양 방법 | |
| WO2021055697A3 (en) | Immunoactive microparticles and uses thereof | |
| US20170216354A1 (en) | Clinically useful non-antigen pulsed dendritic cells | |
| WO2017142014A1 (ja) | 炎症性疾患を対象とした医薬 | |
| EP1352955A3 (en) | HLA matching donor-originating activated lymphocytes to be used in prevention/treatment of tumors, infectious diseases and autoimmune diseases, treatment method achieved by using the lymphocytes, formula having the lymphocytes as a main constitutuent thereof, method for manufacturing the formula and preparation kit to be used to prepare the formula | |
| CN103243072A (zh) | CD8α-白介素21片段-CD137复合物扩增激活淋巴细胞的方法 | |
| Molina et al. | A review of IMMUNEPOTENT CRP, a modifier of biological response: efficacy and current practice | |
| CN105198790B (zh) | 促进双阴性t细胞体外增殖的四环化合物 | |
| Silvestre et al. | Engineered CD19-CAR NK cells as an off-the-shelf alternative to B cell leukemia and lymphoma treatment | |
| RU2474421C1 (ru) | Способ профилактики осложнений при лечении больных раком легкого | |
| Zhi et al. | Myeloid derived suppressor cells: subsets, expansion, and role in cancer progression | |
| Nonoka et al. | INVESTIGATION OF CHANGES IN ANTIOXIDANT CAPACITY IN RATS EXPOSED TO ULTRASOUND | |
| ZHANG et al. | MITOCHONDRIA-TARGETED NANOPROBE-MEDIATED SONODYNAMIC THERAPY ENHANCES CHEMOIMMUNOTHERAPY FOR BREAST CANCER | |
| Maccalli et al. | Signaling Pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200316 |